On February 10, 2026 Defence Therapeutics Inc. ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, reported on its Scientific Advisory Board ("SAB") meeting held on January 30, 2026, focused on advancing the strategic positioning of Accum for antibody–drug conjugate ("ADC") applications.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The discussion brought together complementary expertise spanning ADC chemistry and development, experimental design and translational science, and value creation and partnering strategy, enabling an in-depth and highly constructive exchange on Accum’s role in improving intracellular delivery of ADC payloads. The conversation focused on identifying the most critical scientific questions to address, refining development priorities, and aligning data generation with the expectations of future clinical and pharmaceutical partners.
"This was an exceptionally valuable discussion that helped us sharpen both our scientific focus and our strategic direction," said Maxime Parisotto, PhD, Chief Scientific Officer of Defence Therapeutics. "The insights shared by our advisors are directly informing how we design our next studies, ensuring that we generate the data that matter most to advance Accum toward the clinic and position the platform for meaningful partnerships."
The discussion benefited from the complementary expertise of Rob Leanna, PhD, whose experience in ADC development, drug–linker chemistry, and clinical advancement was shaped through his long tenure at AbbVie; Danny Chui, PhD, who brought deep insight into ADC design and translational science informed by his significant work at Zymeworks, Abdera Therapeutics, and Kairos Therapeutics; and Brendan Hussey, PhD, who contributed a value-creation and partnering perspective grounded in clinical development, strategy, and capital formation. Together, their input is guiding the next phase of Accum development as the platform advances toward clinical translation and strategic partnerships.
As a result of this multidisciplinary dialogue, Defence Therapeutics is refining its Accum ADC development roadmap to better align platform capabilities with clinical development requirements and partnering considerations, with the goal of enabling more effective and better-tolerated ADC therapies. This approach reinforces Accum’s potential as a next-generation intracellular delivery solution for complex biologics. To explore partnering opportunities or schedule a meeting, please contact [email protected].
(Press release, Defence Therapeutics, FEB 10, 2026, View Source;utm_medium=rss&utm_campaign=defence-therapeutics-aligns-accum-adc-strategy-through-multidisciplinary-scientific-advisory-board [SID1234662562])